Generation monoclonal antibodies against the ECD of transmembrane (TM) receptors

Precision Antibody will be attending Discovery on Target Conference on Oct 8-10, 2014.

If you need monoclonal antibodies developed against membrane-associated targets such as ECD of receptors and channels, we would encourage you to visit Precision Antibody at Booth #20 at the “Discovery on Target” meeting. Precision Antibody, a market leader in contract antibody services, has an unsurpassed track record generating monoclonal antibodies against the ECD of transmembrane (TM) receptors including single pass and multi-pass receptors. The development of antibodies against the receptor ECD is challenging. Accordingly, each project is given special attention and custom design by our team of specialists (aka hybridominators). Each project is tailored using variety of strategically designed immunizing antigens and screening procedures most appropriate for the intended application of the mABs.

Before the project starts, under a CDA, we offer free consultation of your project. We discuss the project in depth with our client to understand the scope and the scale of the project to generate an accurate quote and timeline. Once PO is issued we will provide a detailed statement of work (SOW). A typical TM receptor project takes around 60 to 70 days. Our quotes include phase in pricing to reduce the risk for our clients. All the clones developed for the projects are your property. Precision Antibody does not retain any ownership.

Please visit us at Booth #20 at “Discovery on Target” to discuss your next project or fill out an online quote request.

About Precision Antibody

Precision AntibodyTM provides customized, high-affinity monoclonal and polyclonal antibodies to pharmaceutical and biotechnology companies as well as to academic, government, and nonprofit research institutions. Precision Antibody develops antibodies for the use in research and discovery, for the development of preclinical therapeutic and diagnostic targets, and for QC and PK studies. The company’s products and services are based on a proprietary antibody discovery and development platform technology that enables rapid development of target-specific, high-affinity antibodies. Precision Antibody provides one-stop service from antigen development, antibody development, antibody characterization (isotype and affinity determination), antibody purification/production (from pilot to large scale), assay development, humanization, stable cell line development and hybridoma cell banking. Precision Antibody is a wholly-owned service division of A&G Pharmaceutical, Inc. and is based in Columbia, MD.

About Discovery on Target 2014

Cambridge Healthtech Institute will host its 12th Annual Discovery on Target event showcasing current and emerging “hot” targets for the pharmaceutical industry October 8 – 10, 2014 in Boston, MA. Spanning three days, the meeting attracts 900+ attendees (from 24 countries), composed of scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2014 the event is comprised of 14 meeting tracks which include Epigenetic Readers, Ubiquitin Proteasome, Big Data Discovery, GPCR Drug Discovery, RNAi-Screens-Functional-Genomics, PPI Targets, Protein-Targets, Histone-Methyltransferases-Demethylases, Drug Transporters, Maximizing Efficiency, GPCR Therapeutics, Genomics Screening, Cancer Metabolism and Membrane Production. The 2014 event offers 200+ scientific presentations across these 14 conference tracks, 1 Symposium and 13 conference short courses, 40+ interactive breakout discussion groups, an exhibit hall of 40+ companies, and dedicated poster viewing and networking sessions. The 12th Annual Discovery on Target assembles an impressive group of 195+ distinguished speakers who look forward to sharing their knowledge, best practices, and expertise with all attendees. The event website is